12 February – Webinar in connection with year-end report
Alligator hosted a webinar and conference call for investors, analysts where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the 2025 year-end report. The presentation was followed by a Q&A session.
The recording can be requested via >> this link <<.
19 August – R&D event
Alligator hosted a virtual R&D Day on Tuesday, 19 August 2025 providing an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).
LATEST NEWS
Alligator Bioscience strengthens intellectual property protection for bispecific antibody platform
Lund, Sweden – 10 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing …
Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22
Lund, Sweden – 2 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henl …
Exercise price determined for the exercise of warrants series TO 14 in Alligator Bioscience AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, …